Try our beta test site

Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

This study has been terminated.
Information provided by:
SGX Pharmaceuticals, Inc. Identifier:
First received: January 23, 2008
Last updated: July 22, 2008
Last verified: July 2008
SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.

Condition Intervention Phase
Advanced Cancer
Drug: SGX523 Capsules
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, Ona Twice Daily, Interrupted Schedule in Patients With Advanced Cancer

Resource links provided by NLM:

Further study details as provided by SGX Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Maximum Tolerated Dose [ Time Frame: Within first 28 Days ]

Secondary Outcome Measures:
  • Dose Limiting Toxicities [ Time Frame: Within first 21 days of therapy ]

Estimated Enrollment: 46
Study Start Date: January 2008
Estimated Study Completion Date: June 2009
Estimated Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single arm Drug: SGX523 Capsules
This is a dose escalation study


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has the ability to understand, able, willing to comply with study procedures and follow up visits, and has provided written consent.
  • Pathologic evidence of solid tumor.
  • Failed standard therapy and deemed by the Investigator to be suitable for participation into the trial.
  • Laboratory values (obtained within 10 days prior to enrollment): ANC: >= 1.5 × 109/L; Platelets: >= 100 × 109/L; Hemoglobin: >= 10.0 g/dL (without transfusions); Bilirubin: within normal range; AST, ALT, and alkaline phosphatase: <= 2.5 x ULN without tumor liver involvement; Serum creatinine: within normal limits; Calculated creatinine clearance: >= 60 mL/min/1.73 m2 for patients with creatinine > Institutional Normal Values; PT/PTT/INR: within normal limits.
  • Have IHC evidence of phospho-MET expression on tumor material no more than 12 months old. This is a requirement only for entry into the MTD dose expansion phase.
  • Have no residual toxic effects of previous therapy, and undergo a washout period of at least 5 half-lives from the time of administration of the previous therapy.

Exclusion Criteria:

  • Pregnant, lactating, or may become pregnant.
  • Cardiac disease requiring medical therapy.
  • Have had a major surgery within 4 weeks prior to Day 1 of the study
  • Have an active, uncontrolled bacterial, viral, or fungal infection that requires ongoing systemic therapy.
  • Have a known active infection with HIV, hepatitis B or C.
  • Have psychiatric or seizure disorders that would require therapy or interfere with study participation.
  • Have other severe concurrent nonmalignant disease that could compromise protocol objectives, including malabsorptive conditions.
  • Patients receiving prohibited medications as listed in Appendix E, including drugs categorized as strong inhibitors of CYP3A4 and A5 and drugs known to have a high potential risk of liver toxicity.
  • Have known allergy to SGX523 formulation or its excipients (croscarmellose sodium, lactose monohydrate and magnesium stereate).
  • Patients receiving anti-coagulant therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00607399

United States, Arizona
Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258
Premiere Oncology, Arizona
Scottsdale, Arizona, United States, 85260
Sponsors and Collaborators
SGX Pharmaceuticals, Inc.
Principal Investigator: Michael Gordon, MD Premier Onocology, Arizona
Principal Investigator: Ramesh Ramanathan, MD Scottsdale Healthcare
  More Information

Responsible Party: Terry Rugg, MD, SGX Pharmaceuticals, Inc. Identifier: NCT00607399     History of Changes
Other Study ID Numbers: SGX523-1A-001
Study First Received: January 23, 2008
Last Updated: July 22, 2008

Keywords provided by SGX Pharmaceuticals, Inc.:
Solid tumor
Advanced Cancer
MET Inhibitor
Receptor Tyrosine Kinase Inhibitor (RTKI)

Additional relevant MeSH terms:
Neoplasms processed this record on March 27, 2017